Purpose: To evaluate the intraocular pressure (IOP) reducing effect of a fi xed combination of 0.005% latanoprost and 0.5% timolol in patients with an IOP of 30 mmHg or higher. Design: Prospective, randomized clinical trial. Participants: Twenty-eight patients. Methods: Patients had received no prior medical glaucoma treatment. Routine ophthalmic examinations and visual fi eld tests were performed before and after treatment for each patient. Results: Mean IOP was 32.28 ± 0.92 mmHg before treatment. Mean IOP levels were 18.75 ± 0.68 for the fi rst day, 17.96 ± 0.90 for the fi rst week and 17.64 ± 0.66 for the fi rst month after treatment. Conclusion: A fi xed combination of latanoprost 0.005% and timolol 0.5% is effective in signifi cantly reducing IOP in glaucoma patients with an IOP greater than 30 mmHg.
Introduction
Glaucoma needs to be treated in order to prevent development of additional impairment in the optic disc in the long term and to maintain the intraocular pressure (IOP) level to restrict any potential loss in the visual fi eld or visual acuity. 1 IOP is a correctable factor in glaucoma, and a reduction in IOP can typically be achieved by medication, laser treatment or surgery. The standard approach for medication is to initiate a monotherapy with an individual agent. 2 The prostaglandin analogues, the most common medications indicated, can reduce IOP by up to 30%. Particularly when used in combination, instilling a drop immediately after the fi rst drop of the other agent will result in both removal of the fi rst agent from the fi eld and reduced concentration of the second agent. Studies have shown that administration of more than two drops daily directly reduces patient compliance. Fixed combinations of glaucoma medications reduce the number of bottles of medication patients need to purchase, which can represent a cost saving for those whose drug plan requires a per bottle copayment. 3 Fixed combinations also represent a reduction in the number of drops per day required to be instilled. 3 In this study we evaluated the effi cacy of a fi xed combination of 0.005% latanoprost and 0.5% timolol in lowering the IOP as a fi rst-line therapy in glaucoma patients with an IOP greater than 30 mmHg.
Materials and methods
The study included a total of 28 patients (15 females, 13 males), who had been initially diagnosed with glaucoma in the Glaucoma Unit of the Eye Clinic of the Fatih Sultan Mehmet Training and Research Hospital. Mean age was 58.64 ± 8.84 years.
Patients with primary open angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma were eligible for the study as well as those who had no prior glaucoma treatment, and an IOP higher than 30 mmHg at two measurements within the same day. Preand post-treatment measurements for visual acuity, anterior segment and fundus examination, IOP by Goldmann applanation tonometry, visual fi eld testing (Humphrey 30-2 full threshold) and central corneal thickness were performed for each patient. The IOP measurements were obtained at 8 AM and 4 PM. At each time point, two measurements were taken to provide the mean IOP value. Patients with a contraindication for latanoprost and timolol therapy, a history of angle closure glaucoma, uveitis, surgery or any topical or systemic nonsteroidal anti-infl ammatory drug and steroid use were excluded from the study. One drop of the latanoprost-timolol fi xed combination was applied at 9 PM. The pre-and posttreatment IOP values at day 1, week 1 and month 1 were compared statistically using the Wilcoxon signed-rank test.
Results
Of the eyes included in the study, 21 had primary open angle glaucoma, 6 had pseudoexfoliative glaucoma, and 1 pigmentary glaucoma. Patient demographic characteristics are shown in Table 1 . Treatment was discontinued in 1 patient due to lack of effi cacy. IOP was diminished only 5% in this patient and was not included in the analyses. The mean pre-treatment IOP was 32.28 ± 0.92 mmHg. Following treatment, mean IOP values were: 18.75 ± 0.68 mmHg (p Ͻ 0.05) at day 1; 17.96 ± 0.90 mmHg (p Ͻ 0.05) at week 1; and 17.64 ± 0.66 mmHg (p Ͻ 0.05) at month 1 ( Table 2 ). The reduction in the IOP was -13.53 ± 0.24 mmHg, 14.32 ± 0.02 mmHG, and 14.64 ± 0.26 mmHg at day 1, week 1 and month 1, respectively. A statistically signifi cant difference in IOP values compared to the pre-treatment period was observed for all intervals. The side effects included burning and stinging in 1 patient, redness in 1 patient, and itching in 1 patient.
Discussion
Higher concentrations of prostaglandins (PG) may elevate IOP, resulting in infl ammation of the eye, whereas lower concentrations may reduce IOP by increasing the uveoscleral outfl ow. Latanoprost, released commercially several years ago, is an analogue of an F2α prostaglandin and is highly selective for the FP receptor. 4 PGs bind to the receptors on the ciliary muscles, affecting the uveoscleral outfl ow. By increasing the outfl ow of the aqueous humor through the uveoscleral pathway, latanoprost has an additive effect with agents that elevate the trabecular fl ow and decrease the aqueous production. It is used once daily. 4 IOP can be signifi cantly reduced when latanaprost is added to the regimen in patients with open angle glaucoma which could not be controlled by timolol.
Beta-blockers or prostaglandins are used in the fi rst-line therapy for many glaucoma patients. In cases where a more effective therapy is required, fi xed combination drops with two active agents should be preferred instead of a second agent. Previous studies have shown that the latanoprosttimolol fi xed combination therapy is more effective than the monotherapies alone. 5 Shin et al showed, similar to our study, that the latanoprost-timolol fi xed combination is an effective and safe treatment option in reducing IOP. 6 We found that the latanoprost-timolol fi xed combination used as a fi rst-line therapy reduced IOP by approximately 43% within a short period of time. Furthermore, it has been reported that the mean reduction obtained by a latanoprost-based fi xed combination was 1.0 mmHg higher compared with a dorzolamide-based fi xed combination twice a day, along a diurnal curve with three timepoints. 6 It has been demonstrated that the latanoprost-timolol fi xed combination therapy decreasess IOP by more than 2.9 mmHg compared with timolol alone, and by more than 1.1 mmHg compared with latanoprost alone. 7 Although diverse rates of iris pigmentation have been reported in previous studies, 8, 9 we believe that lack of any iris pigmentation in our cases might have been associated with the shorter study period.
We believe that our study group was preliminary, consisting of a limited number of patients, and patient adherence to the therapy was closely related to once-daily dosage.
In conclusion, our short study has shown that the 0.005% latanoprost and 0.5% timolol fi xed combination is effective in signifi cantly reducing IOP in glaucoma patients with an IOP greater than 30 mmHg.
